Sanuwave Health, Inc. reported second quarter 2026 financial results with revenue of $9.7 million, a 3% decline from the prior year period. Gross margin decreased to 76.2% from 78.1%, and GAAP operating income turned to a loss of $(0.3) million compared to $1.4 million previously. The company withdrew its fiscal year 2026 financial guidance due to uncertainty surrounding CMS reimbursement changes for wound care treatments. System sales declined to 82 units from 116 in the prior year, while applicator revenue grew 13% to $7.3 million. Sanuwave operates in the medical device industry, specializing in FDA-cleared regenerative medicine and wound care products.

Sanuwave Health, Inc. issued a press release on July 13, 2026, announcing preliminary financial results for the quarter ended June 30, 2026. The company is in the healthcare technology industry, providing medical devices and therapeutic solutions.

Sanuwave Health, Inc. issued a press release on June 16, 2026, providing updated financial guidance for the fiscal quarter ending June 30, 2026. The specific details of the updated guidance are contained in the attached Exhibit 99.1. Sanuwave Health, Inc. is a medical technology company.